Latest Peplin news

news

09-Jan-09

Positive results for Peplin's Phase IIb AK Trial read more

16-Dec-08

Peplin completes enrolment for its first phase III AK clinical trial read more

02-Dec-08

Form 10-Q - Quarterly Report read more

Registration statement including financial report read more

Major shareholders

As of 30 June 2008, Peplin stockholders with 5% or greater

Name Listed CDI
Number held Percentage of shares owned
Entities affiliated with MPM BioVentures IV 42,309,620 19.70%
Entities affiliated with Acorn Capital Limited 22,598,120 10.90%
Entities affiliated with Orbis Global Equity Fund Limited 27,545,540 13.20%
Asia Union Investments Pty Limited 23,568,440 11.40%

Contact us

Medical information

Telephone: +1-800-881-5754
Email: peplin@medcomsol.com

Clinical trial information

Please refer to www.clinicaltrials.gov for trial information

Corporate information

Email: info@peplin.com

USA

6475 Christie Avenue
Suite 300
Emeryville, California 94608

Telephone: +1-510 653 9700
Facsimile: +1-510 653 9704

AUSTRALIA

Level 2, Brisbane Portal
1 Breakfast Creek Road
Newstead
Brisbane, Queensland 4006

Telephone: +61-7-3250 1200
Facsimile: +61-7-3250 1299